

Pylera[®] (bismuth subcitrate potassium/metronidazole/tetracycline) – First-time generic

- On March 10, 2023, <u>Par launched</u> an <u>AB-rated</u> generic version of AbbVie's <u>Pylera (bismuth</u> <u>subcitrate potassium/metronidazole/tetracycline)</u> capsules.
- Pylera is approved in combination with omeprazole for the treatment of patients with *Helicobacter pylori* (*H. pylori*) infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate *H. pylori*.
- Pylera carries a boxed warning for potential for carcinogenicity.
- According to IQVIA, Pylera had estimated annual sales of \$30 million in the U.S.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.